Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 7/20 | 0.43 |
| ▸ | CCKBR | P32239 | 7/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14550228 | 1.00 | GLP1R (0.56) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550487 | 0.98 | GLP1R (0.56) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550408 | 0.97 | GLP1R (0.54) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550148 | 0.97 | GLP1R (0.53) | GLP1RTLR2CCKARCCKBRNMT2 | |
| SCHEMBL14550486 | 0.96 | GLP1R (0.55) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550121 | 0.95 | GLP1R (0.53) | GLP1RTLR2CCKARCCKBRNMT2 | |
| SCHEMBL14550380 | 0.94 | GLP1R (0.58) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550136 | 0.92 | GLP1R (0.56) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550143 | 0.92 | GLP1R (0.56) | GLP1RTLR2CCKARCCKBRSIRT5 | |
| SCHEMBL14550540 | 0.92 | GLP1R (0.51) | GLP1RTLR2CCKARCCKBRSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | GLP1R 5/4885TLR2 1212/4885CCKAR 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.